Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Postmenopausal women tired of taking pills to strengthen brittle bones will soon have another option to fight osteoporosis: a twice-yearly injection. The U.S. Food & Drug Administration last week ...

PROLIA (denosumab) 60mg subcutaneous injection by Amgen Amgen announced that the FDA approved a new indication for Prolia (denosumab injection) as a treatment to increase bone mass in men with ...

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women ...

New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. Please see the Important Safety Information below. Important Safety Information (U.S.) Prolia is ...

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...